Adalimumab: Difference between revisions
From IDWiki
No edit summary |
mNo edit summary |
||
| Line 2: | Line 2: | ||
* Indications include [[JIA]], [[RA]], [[Crohn disease]], [[ankylosing spondylitis]], chronic plaque [[psoriasis]], and [[psoriatic arthritis]] |
* Indications include [[JIA]], [[RA]], [[Crohn disease]], [[ankylosing spondylitis]], chronic plaque [[psoriasis]], and [[psoriatic arthritis]] |
||
* Infectious complications include bacterial infections (including severe [[pneumonia]]), [[TB]], [[candidiasis]], [[CMV]], [[toxoplasmosis]], and [[nocardiosis]] |
* Infectious complications include bacterial infections (including severe [[pneumonia]]), [[TB]], [[candidiasis]], [[CMV]], [[toxoplasmosis]], and [[nocardiosis]] |
||
[[Category:TNF-α inhibitors]] |
|||
[[Category: |
[[Category:Monoclonal antibodies]] |
||
Latest revision as of 00:43, 17 March 2022
- Human IgG1 monoclonal antibody against TNF-α
- Indications include JIA, RA, Crohn disease, ankylosing spondylitis, chronic plaque psoriasis, and psoriatic arthritis
- Infectious complications include bacterial infections (including severe pneumonia), TB, candidiasis, CMV, toxoplasmosis, and nocardiosis
